psyence logo.png
Psyence Group Corporate Update
June 02, 2022 07:00 ET | Psyence Group Inc.
Highlights: Partnership with CRO Clerkenwell Health to design and deliver Psyence’s UK clinical trial progressing; exclusive licensing agreement with Filament HealthDr. Clive Ward-Able has been...
psyence logo.png
Psyence Taps Another Pharma Exec to Drive its Clinical Program
May 31, 2022 14:50 ET | Psyence Group Inc.
TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
psyence logo.png
Psyence and Filament Health Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products
April 19, 2022 07:00 ET | Psyence Group Inc.
VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc (CSE: PSYG | OTCQB: PSYGF) (“Psyence”), a life science biotechnology company pioneering the use of natural...
psyence logo.png
Psyence Group Announces DTC Eligibility Approval in the U.S.
February 09, 2022 07:00 ET | Psyence Group Inc.
TORONTO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
psyence logo.png
Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility
February 07, 2022 07:00 ET | Psyence Group Inc.
TORONTO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
psyence logo.png
Psyence looks to expand capital market opportunities in the UK and Europe
January 21, 2022 10:16 ET | Psyence Group Inc.
TORONTO, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
psyence logo.png
Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6
December 03, 2021 10:30 ET | Psyence Group Inc.
TORONTO, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
psyence logo.png
Psyence Group Announces Private Placement
December 02, 2021 17:30 ET | Psyence Group Inc.
TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
211201 PSYG NR Image 1
Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out in South Africa’s Largest Coffee Retail Chain
December 02, 2021 07:30 ET | Psyence Group Inc.
TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics...
psyence logo.png
Psyence Group Inc. files Q2 Unaudited Condensed Consolidated Interim Financial Statements and MD&A
November 26, 2021 17:30 ET | Psyence Group Inc.
TORONTO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company with a focus on natural psychedelics in...